US Pharma MarketingHaisco grants license to Sentivera; ViiV
Haisco licenses inflammatory drug to Sentivera for $40M upfront, $36M stock, $1.46B milestones; FDA OKs ViiV Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing…
Haisco Pharmaceutical licenses inflammatory disease drug to Sentivera: The Chinese biotech is granting ex-China rights for the unnamed candidate to US startup Sentivera, which was founded by ARCH Venture Partners and Population ...
Source: Endpoints News